Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

SZSE:002675 Voorraadrapport

Marktkapitalisatie: CN¥10.7b

Yantai Dongcheng Pharmaceutical GroupLtd Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Yantai Dongcheng Pharmaceutical GroupLtd's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 0.1% per year. Yantai Dongcheng Pharmaceutical GroupLtd's return on equity is 1.2%, and it has net margins of 3.2%.

Belangrijke informatie

-7.0%

Groei van de winst

-7.5%

Groei van de winst per aandeel

Biotechs Groei van de industrie11.3%
Inkomstengroei-0.1%
Rendement op eigen vermogen1.2%
Nettomarge3.2%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

May 05
Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

Recent updates

Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet

Aug 23
Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price

Jul 12
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price

News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat

May 06
News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat

Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

May 05
Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Mar 15
Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Feb 27
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Opbrengsten en kosten

Hoe Yantai Dongcheng Pharmaceutical GroupLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

SZSE:002675 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 242,85391696226
30 Jun 242,911137679204
31 Mar 243,072224689195
31 Dec 233,276210749197
30 Sep 233,427263796189
30 Jun 233,603323849180
31 Mar 233,554302847174
01 Jan 233,583307788164
30 Sep 223,858220804145
30 Jun 223,851165802146
31 Mar 223,902140791144
01 Jan 223,912152804138
30 Sep 213,637341759129
30 Jun 213,599353860117
31 Mar 213,596411895122
31 Dec 203,419418898109
30 Sep 203,3952141,010104
30 Jun 203,312196991103
31 Mar 203,1721641,02292
31 Dec 192,9931551,00189
30 Sep 192,87736697662
30 Jun 192,70934788474
31 Mar 192,46730279372
31 Dec 182,33328073265
30 Sep 182,09822858699
30 Jun 181,84221251568
31 Mar 181,67918547848
31 Dec 171,59617344940
30 Sep 171,5111724710
30 Jun 171,3771494070
31 Mar 171,2451453510
31 Dec 161,1581313110
30 Sep 161,0141192470
30 Jun 16903952230
31 Mar 16852831940
31 Dec 15795901750
30 Sep 15725941220
30 Jun 15724991190
31 Mar 157271031230
31 Dec 147511041190
30 Sep 14786991240
30 Jun 14783961050
31 Mar 1478291890
31 Dec 13775101770

Kwaliteitswinsten: 002675 has high quality earnings.

Groeiende winstmarge: 002675's current net profit margins (3.2%) are lower than last year (7.7%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: 002675's earnings have declined by 7% per year over the past 5 years.

Versnelling van de groei: 002675's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: 002675 had negative earnings growth (-65.5%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).


Rendement op eigen vermogen

Hoge ROE: 002675's Return on Equity (1.2%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden